The Coronavirus Aid, Relief, and Economic Security (CARES) Act encourages charitable giving by increasing tax incentives for individuals and corporations. We want to make sure that anyone who supports us […]
CureDuchenne is pleased to share the news that Edgewise Therapeutics is starting a Phase 1 clinical trial to assess the safety, tolerability, and appropriate dose of their experimental therapeutic aimed […]
CureDuchenne Ventures is happy to announce an investment in Mesentech, a company based in Vancouver, Canada, that has a novel therapeutic approach for improving bone density and strength. This investment […]
Get Involved with Project Euphonia Help future generations of people living with motor speech impairments. Automated speech recognition, which powers voice-activated technology such as the Google Assistant, are more common […]
CureDuchenne congratulates the incredible Dyne Therapeutics team, who recently announced closing $115M in equity financing to develop transformational therapies for patients with serious muscle diseases. We share this news in […]
CureDuchenne is very proud that Dr. Kevin Flanigan, at Nationwide Children’s Hospital, has treated two patients with gene therapy that carry the Duplication 2 mutation. CureDuchenne funded Dr. Flanigan’s very […]
Take this Survey by July 19! CureDuchenne is supporting the EveryLife Foundation for Rare Diseases in their effort to conduct a survey of families living with rare diseases. This survey […]
Friday, May 15, 2020 – 8:00amEDT Pfizer Inc. (NYSE: PFE) today announced updated Phase 1b clinical data on PF-06939926, an investigational gene therapy being developed to treat Duchenne muscular dystrophy […]
